{
    "root": "30c7197b-7111-d8a7-e063-6394a90addfb",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Diclofenac Potassium",
    "value": "20250301",
    "ingredients": [
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYDEXTROSE",
            "code": "VH2XOU12IE"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "DICLOFENAC POTASSIUM",
            "code": "L4D5UA6CB4"
        }
    ],
    "indications": "carefully consider potential benefits risks diclofenac potassium tablets treatment options deciding diclofenac potassium tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( : gastrointestinal bleeding , ulceration , perforation ) . diclofenac potassium tablets indicated : \u2022for treatment primary dysmenorrhea \u2022for relief mild moderate pain \u2022for relief signs symptoms osteoarthritis \u2022for relief signs symptoms rheumatoid arthritis",
    "contraindications": "carefully consider potential benefits risks diclofenac potassium tablets treatment options deciding diclofenac potassium tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( : gastrointestinal bleeding , ulceration , perforation ) . observing response initial therapy diclofenac potassium tablets , dose frequency adjusted suit individual patient \u2019 needs . treatment pain primary dysmenorrhea recommended 50 mg three times day . experience , physicians may find patients initial dose 100 mg diclofenac potassium tablets , followed 50 mg doses , provide better relief . relief osteoarthritis recommended 100-150 mg/day divided doses , 50 mg twice day three times day . relief rheumatoid arthritis recommended 150-200 mg/day divided doses , 50 mg three times day four times day . different formulations diclofenac ( diclofenac sodium enteric-coated tablets ; diclofenac sodium extended-release tablets ; diclofenac potassium immediate-release tablets ) necessarily bioequivalent even milligram strength .",
    "warningsAndPrecautions": "diclofenac potassium tablets , usp available containing 50 mg diclofenac potassium , usp . 50 mg tablets white , film-coated , round , unscored tablets debossed d5 one side tablet blank side . available follows : ndc 10135-0806-01 bottles 100 tablets store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] protect moisture . dispense tight , light-resistant container defined usp using child-resistant closure . pharmacist : dispense medication guide prescription . revised : 03/2025",
    "adverseReactions": "diclofenac potassium tablets contraindicated following patients : \u2022known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac components product ( : anaphylactic , serious skin ) . \u2022history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients ( : anaphylactic , exacerbation asthma related aspirin sensitivity ) . \u2022in setting coronary artery bypass graft ( cabg ) surgery ( : cardiovascular thrombotic events ) .",
    "indications_original": "Carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS: Gastrointestinal Bleeding, Ulceration, and Perforation).\n                  Diclofenac potassium tablets are indicated:\n                  \u2022For treatment of primary dysmenorrhea\n                  \u2022For relief of mild to moderate pain\n                  \u2022For relief of the signs and symptoms of osteoarthritis\n                  \u2022For relief of the signs and symptoms of rheumatoid arthritis",
    "contraindications_original": "Carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS: Gastrointestinal Bleeding, Ulceration, and Perforation).\n                  After observing the response to initial therapy with diclofenac potassium tablets, the dose and frequency should be adjusted to suit an individual patient\u2019s needs.\n                  For treatment of pain or primary dysmenorrhea the recommended dosage is 50 mg three times a day. With experience, physicians may find that in some patients an initial dose of 100 mg of diclofenac potassium tablets, followed by 50 mg doses, will provide better relief.\n                  For the relief of osteoarthritis the recommended dosage is 100-150 mg/day in divided doses, 50 mg twice a day or three times a day.\n                  For the relief of rheumatoid arthritis the recommended dosage is 150-200 mg/day in divided doses, 50 mg three times a day or four times a day.\n                  Different formulations of diclofenac (diclofenac sodium enteric-coated tablets; diclofenac sodium extended-release tablets; diclofenac potassium immediate-release tablets) are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions_original": "Diclofenac Potassium Tablets, USP are available containing 50 mg of diclofenac potassium, USP.\n                  The 50 mg tablets are white, film-coated, round, unscored tablets debossed with \n  M over \n  D5 on one side of the tablet and blank on the other side. They are available as follows:\n \n                  NDC 10135-0806-01\n  \n                     \nbottles of 100 tablets\n \n                  \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]\n                  \n                  \n                     Protect from moisture.\n                  \n                  Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.\n                  \n                     PHARMACIST:Dispense a Medication Guide with each prescription.\n \n                  Revised: 03/2025",
    "adverseReactions_original": "Diclofenac potassium tablets are contraindicated in the following patients:\n                  \u2022Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see WARNINGS: Anaphylactic Reactions, Serious Skin Reactions).\n                  \u2022History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see WARNINGS: Anaphylactic Reactions, Exacerbation of Asthma Related to Aspirin Sensitivity).\n                  \u2022In the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS: Cardiovascular Thrombotic Events)."
}